



**FOR APPROVAL**

**PUBLIC**

**OPEN SESSION**

**TO:** Academic Affairs Committee

**SPONSOR:** Amrita Daniere, Vice-Principal Academic and Dean  
**CONTACT INFO:** 905-828-3719, [vpdean.utm@utoronto.ca](mailto:vpdean.utm@utoronto.ca)

**PRESENTER:** Leigh Revers, Director, Master of Biotechnology Program  
**CONTACT INFO:** 416-705-5735, [leigh.revers@utoronto.ca](mailto:leigh.revers@utoronto.ca)

**DATE:** April 18 , 2017 for April 25, 2017

**AGENDA ITEM:** 4

**ITEM IDENTIFICATION:**

Minor Modification: Master of Biotechnology Program (Mbiotech) Course Name Change

**JURISDICTIONAL INFORMATION:**

Under section 5.6 of its terms of reference, the Academic Affairs Committee is responsible for major and minor modifications to existing programs.

**GOVERNANCE PATH:**

- 1. Academic Affairs Committee [For Approval] (April 25, 2017)**

**PREVIOUS ACTION TAKEN:**

No previous action has been taken.

**HIGHLIGHTS:**

The University of Toronto Mississauga (UTM) currently houses five Professional Graduate Masters Programs under the Institute for Management of Innovation (IMI), including the Master of Biotechnology Program (Mbiotech). In a continuing effort to provide the best support for their students, the Mbiotech Program is proposing a name change to the existing BTC1810H course from *Biotechnology & Ventures* to *Biotechnology & Drug Manufacturing*.

In the first year of the Mbiotech program, students are required to complete BTC1810H. The goal of this course is to introduce students to key aspects of the biocommercialization process with special emphasis on the healthcare sector and particular focus on the fundamental role played by corporate entities in the development of new therapeutic drugs and diagnostic tools in a highly regulated business environment. In order to help students better understand the road from product concept to product development to commercialization, a new course title,

*Biotechnology & Drug Manufacturing*, is being proposed. This change will highlight for students the importance of having an appreciation of the scalable biological processes that are used for product manufacturing; the need to learn about the use of biopharmaceutical manufacturing in emergency responses like pandemics; and the importance of understanding the regulatory pathway from the three clinical phases to commercialization to the post-market.

This proposed course change was reviewed and approved by the IMI Curriculum Committee on May 31, 2016.

There are no resource implications for this change.

**FINANCIAL IMPLICATIONS:**

There are no net implications for the campus' operating budget.

**RECOMMENDATION:**

Be it Resolved,

THAT the course name change as proposed by the Master of Biotechnology Program, offered by the Institute for Management and Innovation (IMI), recommended by the Vice-Principal Academic & Dean, Professor Amrita Daniere, and described in the proposal dated March 23, 2017, be approved, effective on May 1, 2017.

---

**DOCUMENTATION PROVIDED:**

Item Course Name Change: BTC1810H



# University of Toronto Minor Modification Proposal – New Graduate Courses, or Changes to Existing Graduate Courses

***This template should be used to: create a new graduate course; reactivate a closed/deactivated course; rename an existing course; renumber an existing course; etc. A complete list of all course changes is available on the [Vice-Provost, Academic Programs website](#).***

*If you have questions while you are filling out this document, please contact your Dean’s Office.*

<b>Graduate Department /Unit/Centre/Institute:</b> <i>For courses offered by collaborative programs list supporting unit.</i>	Institute for Management & Innovation (IMI)
<b>Faculty / Academic Division:</b>	University of Toronto Mississauga (UTM)
<b>Dean’s Office contact:</b>	Yen Du Program & Curriculum Officer <a href="mailto:yen.du@utoronto.ca">yen.du@utoronto.ca</a>

## **Part 1: ROSI** *Please complete this section. The data will be used to complete the ROSI record.*

<b><i>Or Changes to an Existing Course (require unit level approval only) – fill out applicable fields</i></b>	
Current Course Designator and Number (required):	<i>BTC1810H</i>
New/Renamed Full Course Title for Transcript:	<i>Biotechnology &amp; Drug Manufacturing</i>
New/Renamed Abbreviated Title:	<i>Biotech &amp; Drug Manufacturing</i>

## **Effective Date**

May 2017
----------

## **Part 2: Other Changes to Existing Courses**

***Optional Field – This section may be used to describe other types of changes to existing courses your Faculty/Division tracks. These changes are not posted to the GCT.***

<p>This is a proposal to change the title of the existing BTC1810H course from <i>Biotechnology &amp; Ventures</i> to <i>Biotechnology &amp; Drug Manufacturing</i>.</p> <p>BTC1810H is a required course for first year MBiotech students. The course introduces students to key aspects of the biocommercialization process with special emphasis on the healthcare sector and particular focus on the fundamental role played by corporate entities in the development of new therapeutic drugs and diagnostic tools in a highly regulated business environment.</p> <p>The proposed course name change is to help students better understand the road from product concept to product development to commercialization. In this course, it is fundamental that students understand the</p>
--

importance in scalable biological processes that are used for manufacturing of the product. Students will also learn the use of biopharmaceutical manufacturing to emergency response like a pandemic. In addition, students will understand the regulatory pathway from the three clinical phases to commercialization and finally to the post-market.

There are no resource implications associated with the change.

## Governance Approval

<b>Unit Sign-Off</b> (Committee name and meeting date)	<b>IMI Curriculum Committee</b> <b>May 31<sup>st</sup>, 2016</b>
<b>Faculty/Division Council</b> (Name and Date)	<b>Academic Affairs Committee</b>